Literature DB >> 8210997

Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus.

H Carlsten1, A Tarkowski.   

Abstract

A number of studies have demonstrated that oestrogen exerts a significant impact on the course of experimental autoimmune diseases. Exposure to oestrogen aggravates SLE glomerulonephritis whereas the opposite outcome has been demonstrated in experimental arthritis, vasculitis, thyroiditis, and sialadenitis. In this report we have analysed the respective impact of H-2z linked gene products and long-term treatment with physiological doses of oestradiol on clinical and immunological variables in castrated backcrosses of lupus prone NZB/W and NZB mice. Our results demonstrate that H-2z linked gene products accelerate B-cell activation and stimulate autoantibody production resulting in aggravation of glomerulonephritis and precocious death in renal failure. These H-2z linked gene products do not influence T-cell mediated sialadenitis. Irrespectively of the H-2 haplotype of the mice, administration of oestrogen resulted in intense polyclonal B cell activation and aggravation of glomerulonephritis. However, exposure to oestrogen resulted in amelioration of sialadenitis. Notably, our result indicates that B-cell activation achieved by oestrogen and H-2z gene linked products, respectively is mediated by independent mechanisms. In addition, we have developed a predictive in vivo test that permits forecasts regarding efficiency of oestrogen treatment for suppression of T-cell mediated lesions. Using this test procedure in young, clinically healthy SLE mice we have been able to prove that animals displaying suppressed delayed type hypersensitivity (DTH) after short-term oestrogen exposure showed significantly lower long-term morbidity regarding development of sialadenitis upon continuous treatment with physiological doses of oestradiol.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8210997     DOI: 10.1111/j.1365-3083.1993.tb01736.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice.

Authors:  H Carlsten; M Verdrengh; M Taube
Journal:  Inflamm Res       Date:  1996-01       Impact factor: 4.575

Review 2.  Gender and age influence on clinical and laboratory features in Chinese patients with systemic lupus erythematosus: 1,790 cases.

Authors:  Jin-Bao Feng; Jin-Dong Ni; Xi Yao; Hai-Feng Pan; Xiang-Pei Li; Jian-Hua Xu; Fa-Ming Pan; Sheng-Qian Xu; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2009-08-23       Impact factor: 2.631

3.  Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice.

Authors:  Giuseppina Caligiuri; Mats Rudling; Véronique Ollivier; Marie-Paule Jacob; Jean-Baptiste Michel; Göran K Hansson; Antonino Nicoletti
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

4.  Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus.

Authors:  Y J Lee; K S Shin; S W Kang; C K Lee; B Yoo; H S Cha; E M Koh; S J Yoon; J Lee
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

5.  Therapeutic effects of estradiol benzoate on development of collagen-induced arthritis (CIA) in the Lewis rat are mediated via suppression of the humoral response against denatured collagen type II (CII).

Authors:  Y Waksman; I Hod; A Friedman
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

6.  Effects of altered prenatal hormonal environment on expression of autoimmune disease in NZB/NZW mice.

Authors:  S E Walker; L W Keisler; C W Caldwell; A B Kier; F S vom Saal
Journal:  Environ Health Perspect       Date:  1996-08       Impact factor: 9.031

Review 7.  Mechanisms of hypertension in autoimmune rheumatic diseases.

Authors:  Erin B Taylor; Victoria L Wolf; Elena Dent; Michael J Ryan
Journal:  Br J Pharmacol       Date:  2019-03-18       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.